Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter phase II trial including 2 cohorts of patients in
Refractory/Relapse disease at least 1 month after CAR T-cells therapy:
- cohort 1: DLBCL patients
- cohort 2: PMBL, mantle cell lymphoma, transformed indolent NHL (t-iNHL) or iNHL CAR
T-cells Refractory/Relapse status will be determined by PET-CT central review allowing
inclusion in this trial.
Patients enrolled will then receive a pre-phase of obinutuzumab followed by experimental
treatment:11 cycle of glofitamab.
The primary objective of the study is to assess the anti-lymphoma activity of glofitamab, a
bispecific CD3xCD20 monoclonal antibody in patients with relapse/refractory DLBCL (cohort 1)
disease after anti-CD19 CAR T-cells therapy